Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia February 3, 2026 10:30 AM EST
Company Participants
Rémy Luthringer – Executive Chairman & CEO
Conference Call Participants
Gregory Strauss
Brian W. Kirkpatrick
Corey Davis – Lifesci Advisors, LLC
Lin Tsai – Jefferies LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, and welcome to the Minerva Neurosciences Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Minerva website following the conclusion of the event.
I’d now like to turn the call over to your host, Remy Luthringer, Executive Chairman and Chief Executive Officer at Minerva Neurosciences. Please go ahead, Remy.
Rémy Luthringer
Executive Chairman & CEO
Thank you so much. Good morning, everybody. It’s a real great pleasure to give you an update on Minerva progress in bringing roluperidone to patients afflicted by schizophrenia and suffering from negative symptoms. And we all know that negative symptoms is the type of symptoms, which is keeping these patients out of any decent life. And it is true that over several decades of research and failed clinical trials, we have not obtained a drug which is helping these patients.
I think today, this unmet medical need becomes a reality. And I think we are at the stage where roluperidone is probably the first treatment for negative symptoms in patients suffering from schizophrenia.
Next slide. So this is just a disclosure. I will not insist on this one. So I’m very, very honored and very pleased to have with me today Professor Gregory Strauss and Professor Brian Kirkpatrick. It would be difficult to give their complete CV, but what I can say just simply is that, I think Greg and Brian have contributed enormously to
